Apyx Medical (APYX) Research & Development (2011 - 2026)

Apyx Medical (APYX) has reported Research & Development for 16 consecutive years, with $793000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 3.76% year-over-year to $793000.0; the trailing twelve-month figure through Jun 2026 stood at $3.3 million (down 14.77% YoY), and the FY2025 full-year result was $3.4 million, down 33.33% from the prior year.
• Research & Development advanced to $793000.0 in Q2 2026 per APYX's latest filing, from $765000.0 in the prior quarter.
• Across five years, Research & Development topped out at $1.4 million in Q2 2024 and bottomed at $765000.0 in Q1 2026.
• Historically, Research & Development has averaged $1.1 million across 5 years, with a median of $1.1 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Research & Development jumped 32.8% in 2023, then tumbled 42.45% in 2025.
• Over 5 years, Research & Development stood at $1.3 million in 2022, then increased by 11.79% to $1.4 million in 2023, then slipped by 18.96% to $1.1 million in 2024, then dropped by 14.6% to $971000.0 in 2025, then fell by 18.33% to $793000.0 in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $793000.0, $765000.0, and $971000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.